The Role of Investigational Therapy in Management of Patients With Advanced Metastatic Malignancy

被引:23
作者
Freireich, Emil J. [1 ]
Kurzrock, Razelle [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Special Med Educ Programs, Houston, TX 77030 USA
关键词
PHASE-1 ONCOLOGY TRIALS; BENEFITS; RISKS;
D O I
10.1200/JCO.2008.19.6543
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
引用
收藏
页码:304 / 306
页数:3
相关论文
共 3 条
[1]
The role of chemotherapy at the end of life: "When is enough, enough?" [J].
Harrington, Sarah Elizabeth ;
Smith, Thomas J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (22) :2667-E1
[2]
Risks and benefits of phase 1 oncology trials, 1991 through 2002 [J].
Horstmann, E ;
McCabe, MS ;
Grochow, L ;
Yamamoto, S ;
Rubinstein, L ;
Budd, T ;
Shoemaker, D ;
Emanuel, EJ ;
Grady, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09) :895-904
[3]
Risks and benefits of phase 1 oncology trials, revisited [J].
Kurzrock, R ;
Benjamin, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09) :930-932